Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 3
1948 11
1949 8
1950 2
1951 2
1952 1
1953 1
1955 4
1956 2
1957 4
1958 3
1959 5
1960 3
1961 15
1962 13
1963 29
1964 85
1965 87
1966 88
1967 132
1968 122
1969 139
1970 161
1971 184
1972 192
1973 207
1974 242
1975 244
1976 321
1977 383
1978 386
1979 381
1980 465
1981 413
1982 489
1983 495
1984 645
1985 675
1986 655
1987 625
1988 632
1989 799
1990 894
1991 830
1992 1041
1993 1050
1994 1289
1995 1320
1996 1502
1997 1549
1998 1698
1999 1816
2000 2177
2001 2184
2002 2339
2003 2652
2004 2823
2005 3221
2006 3455
2007 3608
2008 3977
2009 4231
2010 4906
2011 5334
2012 5771
2013 5915
2014 6310
2015 6795
2016 6927
2017 7150
2018 7543
2019 6935
2020 2745
Text availability
Article attribute
Article type
Publication date

Search Results

108,864 results
Results by year
Filters applied: . Clear all
Page 1
The timing of breast and axillary surgery after neoadjuvant chemotherapy for breast cancer.
Al-Hilli Z, Boughey JC. Al-Hilli Z, et al. Chin Clin Oncol. 2016 Jun;5(3):37. doi: 10.21037/cco.2016.03.26. Epub 2016 Apr 22. Chin Clin Oncol. 2016. PMID: 27164853 Free article. Review.
Neoadjuvant chemotherapy (NAC) has traditionally been used in locally advanced and inflammatory breast cancer, allowing for a reduction in disease volume and therefore optimizing surgical resection of disease in the breast. ...The aim of this review is …
Neoadjuvant chemotherapy (NAC) has traditionally been used in locally advanced and inflammatory breast cancer, allowing …
Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis.
Green AK, Aviki EM, Matsoukas K, Patil S, Korenstein D, Blinder V. Green AK, et al. Breast Cancer Res Treat. 2018 Nov;172(2):247-263. doi: 10.1007/s10549-018-4909-5. Epub 2018 Aug 9. Breast Cancer Res Treat. 2018. PMID: 30094552 Free PMC article.
PURPOSE: We conducted a systematic review and meta-analysis to measure the extent to which race is associated with delayed initiation or receipt of inadequate chemotherapy among women with early-stage breast cancer. ...Eligible studies were US-based and exami …
PURPOSE: We conducted a systematic review and meta-analysis to measure the extent to which race is associated with delayed initiation or rec …
Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.
Goldvaser H, Majeed H, Ribnikar D, Šeruga B, Ocaña A, Cescon DW, Amir E. Goldvaser H, et al. Breast Cancer Res Treat. 2018 Jun;169(3):413-425. doi: 10.1007/s10549-018-4710-5. Epub 2018 Feb 8. Breast Cancer Res Treat. 2018. PMID: 29423899 Review.
PURPOSE: Results from clinical trials of adjuvant dose-dense chemotherapy in patients with breast cancer are inconsistent. METHODS: A systematic search of MEDLINE identified studies comparing the efficacy of dose-dense adjuvant chemotherapy to a standa …
PURPOSE: Results from clinical trials of adjuvant dose-dense chemotherapy in patients with breast cancer are inconsiste …
[Systemic treatment of early breast cancer - current state of knowledge after the conference St Gallen 2017].
Sarosiek T. Sarosiek T. Pol Merkur Lekarski. 2017 Nov 23;43(257):232-236. Pol Merkur Lekarski. 2017. PMID: 29231918 Review. Polish.
Breast cancer is the most commonly diagnosed malignancy in women around the globe. It is also the world's first cause of female deaths from cancer. ...The international biennial St Gallen conference, the world's most prominent breast c
Breast cancer is the most commonly diagnosed malignancy in women around the globe. It is also the world's first cause o
Support with nutrition for women receiving chemotherapy for breast cancer.
Gilmour F, Williams A. Gilmour F, et al. Br J Nurs. 2018 Feb 22;27(4):S4-S9. doi: 10.12968/bjon.2018.27.4.S4. Br J Nurs. 2018. PMID: 29457937 Review.
Nurses are in a unique position to provide nutritional advice and information to women with breast cancer who are undergoing chemotherapy, supporting them with making decisions regarding nutrition and diet. ...Weight gain was identified as a specific problem …
Nurses are in a unique position to provide nutritional advice and information to women with breast cancer who are undergoing …
Drug Combinations in Breast Cancer Therapy.
Fisusi FA, Akala EO. Fisusi FA, et al. Pharm Nanotechnol. 2019;7(1):3-23. doi: 10.2174/2211738507666190122111224. Pharm Nanotechnol. 2019. PMID: 30666921 Free PMC article. Review.
Breast cancer therapy involves a multidisciplinary approach comprising surgery, radiotherapy, neoadjuvant and adjuvant therapy. Effective therapy of breast cancer requires maximum therapeutic efficacy, with minimal undesirable effe
Breast cancer therapy involves a multidisciplinary approach comprising surgery, radiotherapy, neoadjuvant and adjuvant
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2015 Oct 3;386(10001):1353-1361. doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Lancet. 2015. PMID: 26211824 Free article.
We undertook collaborative meta-analyses to clarify the risks and benefits of adjuvant bisphosphonate treatment in breast cancer. ...No differences were seen in non-breast cancer mortality. Bone fractures were reduced (RR 0·85, 95% CI 0·75-0·97; 2p=0·0 …
We undertook collaborative meta-analyses to clarify the risks and benefits of adjuvant bisphosphonate treatment in breast cancer
Progress in adjuvant systemic therapy for breast cancer.
Pondé NF, Zardavas D, Piccart M. Pondé NF, et al. Nat Rev Clin Oncol. 2019 Jan;16(1):27-44. doi: 10.1038/s41571-018-0089-9. Nat Rev Clin Oncol. 2019. PMID: 30206303 Review.
The prognosis of patients with early stage breast cancer has greatly improved in the past three decades. Following the first adjuvant endocrine therapy and chemotherapy trials, continuous improvements of clinical outcomes have been achieved through int …
The prognosis of patients with early stage breast cancer has greatly improved in the past three decades. Following the first a …
Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Sulai NH, Tan AR. Sulai NH, et al. Clin Adv Hematol Oncol. 2018 Jul;16(7):491-501. Clin Adv Hematol Oncol. 2018. PMID: 30067621 Review.
In 2018, olaparib became the first oral PARP inhibitor to receive approval in the United States for the treatment of advanced BRCA-mutated breast cancer, an approval that represents a major change in the treatment paradigm for this subtype of breast cancer
In 2018, olaparib became the first oral PARP inhibitor to receive approval in the United States for the treatment of advanced BRCA-mutated …
Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer.
Read RL, Flitcroft K, Snook KL, Boyle FM, Spillane AJ. Read RL, et al. ANZ J Surg. 2015 May;85(5):315-20. doi: 10.1111/ans.12975. Epub 2015 Jan 22. ANZ J Surg. 2015. PMID: 25612239 Review.
Neoadjuvant chemotherapy (NAC) is a legitimate alternative to first-line surgical therapy for the treatment of breast cancer patients, as level one evidence shows the effect on overall survival is equivalent to that of adjuvant chemotherapy. ... …
Neoadjuvant chemotherapy (NAC) is a legitimate alternative to first-line surgical therapy for the treatment of breast
108,864 results
Jump to page
Feedback